Since IL-17 promotes inflammation, blood coagulation, and thrombosis in arteries and cardiomyocytes [35], inhibiting IL-17 expression or reducing its interaction with its cognate receptor could become beneficial in treating cardiovascular disease in RA patients [36]. This evidence concerns the gene IL17A and cardiovascular disorder.